Pasithea Therapeutics Corp. — Cyborg Score 4/10

Mixed
Clinical-stage biotechnology - rare genetic disease therapeutics

Strategic Profile

PAS-004 is being developed to treat a range of RASopathies, including neurofibromatosis type 1 (NF1), MAPK pathway-driven tumors, and ETS2 driven diseases including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. Pasithea appointed Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer effective May 1, 2026.

Cyborg Score Rationale

In Q1 2026, KTTA reported EPS of -$0.12, beating estimates of -$0.45. The company is advancing clinical candidates with FDA designations (Fast Track and Rare Pediatric Disease Designation for PAS-004), demonstrating regulatory momentum. However, as an early-stage biotech with minimal revenue and a small team, execution risk remains substantial.

Top Insights

  • Appointed experienced CMO Kartik Krishnan effective May 2026 to lead clinical development strategy
  • Q1 2026 EPS beat expectations significantly, moving losses toward potential breakeven metrics
  • Portfolio focused on high-unmet-need indications (NF1, ALS, IBD) with regulatory fast-track designation
  • Company currently operates with only 5 employees, suggesting outsourced development model

Named Competitors

  • MEK inhibitors — MEK inhibitor therapies in oncology and RASopathies
  • RASopathy treatments — MEK inhibitors for neurofibromatosis type 1
  • ALS therapeutics — Neurodegenerative disease treatments

Recent Developments

  • (May 2026) Appointed Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer
  • (April 2026) Granted Rare Pediatric Disease Designation by FDA for PAS-004
  • (April 2026) Granted Fast Track Designation by FDA for PAS-004 in NF1-associated plexiform neurofibromas
  • (Q1 2026) Reported stronger-than-expected earnings, beating EPS estimates

Open the full interactive Pasithea Therapeutics Corp. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →